Vaidyanathan G, Friedman H S, Keir S T, Zalutsky M R
Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Br J Cancer. 1996 May;73(10):1171-7. doi: 10.1038/bjc.1996.226.
The biodistribution of no-carrier-added (n.c.a.) meta-[131I]iodobenzylguanidine ([131I]MIBG) and that prepared by the standard isotopic exchange method were compared in athymic mice bearing SK-N-SH human neuroblastoma xenografts. No advantage in tumour uptake was observed for the n.c.a. preparation. BALB/c nu/nu mice exhibited lower uptake in highly innervated normal tissues (heart and adrenals) than normal BALB/c mice. In another experiment, the distribution of n.c.a. [131I]MIBG in the absence or presence (3-9 micrograms) of MIBG carrier was determined. At both 4 h and 24 h, the heart uptake was reduced by a factor of 1.5 even at a dose of 3 micrograms MIBG. Tumour uptake was not significantly altered by various amounts of unlabelled MIBG at either time point.
在携带SK-N-SH人神经母细胞瘤异种移植瘤的无胸腺小鼠中,比较了无载体添加(n.c.a.)的间位-[¹³¹I]碘苄胍([¹³¹I]MIBG)和通过标准同位素交换法制备的[¹³¹I]MIBG的生物分布。未观察到无载体添加制剂在肿瘤摄取方面有优势。BALB/c裸鼠在高度神经支配的正常组织(心脏和肾上腺)中的摄取低于正常BALB/c小鼠。在另一项实验中,测定了在不存在或存在(3 - 9微克)MIBG载体的情况下无载体添加的[¹³¹I]MIBG的分布。在4小时和24小时时,即使给予3微克MIBG剂量,心脏摄取也降低了1.5倍。在两个时间点,不同量的未标记MIBG均未显著改变肿瘤摄取。